ASCO Annual Meeting: Breast Cancer | Conference

Sacituzumab Govitecan for Metastatic TNBC Retains Survival Advantage Over Chemotherapy
June 08, 2021

Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician's choice chemotherapy.

Numerically Improved pCR Not Significant With SD-101 Plus Pembrolizumab in HER2– Breast Cancer
June 07, 2021

Some improvement in pathological complete response may be possible with SD-101 plus pembrolizumab and paclitaxel in certain patients with HER2-negative breast cancer, but results are still uncertain.

Ultralow Risk 70-Gene Signature May Indicate Survival Outcomes in Early-Stage Breast Cancer
June 06, 2021

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated an excellent survival prognosis regardless of clinical risk.